Handelsavisen
prelaunch
Companies Healthcare ALINS.PA
AL
ALINS.PA Euronext Paris Advanced Medical Equipment & Technology

Alins.Pa

€0,21
Open in Charts → Attach watcher ⌖
EUR
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
Op margin
-360,4 %
ROE
158,1 %
Net margin
-364,8 %
Debt / equity
-1,36
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

ALINS.PA provides advanced medical equipment and technology solutions, primarily generating revenue through the sale and servicing of diagnostic imaging systems and related healthcare technologies.

Business. ALINS.PA provides advanced medical equipment and technology solutions, primarily generating revenue through the sale and servicing of diagnostic imaging systems and related healthcare technologies.

Classification92 %
SectorHealthcare
Business sectorHealthcare Services & Equipment
IndustryAdvanced Medical Equipment & Technology
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
not yet wired
Ownership
not yet wired
Profitability
158,1 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning ALINS.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to ALINS.PA. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    ALINS.PA provides advanced medical equipment and technology solutions, primarily generating revenue through the sale and servicing of diagnostic imaging systems and related healthcare technologies.

    Classification92 %
    SectorHealthcare
    Business sectorHealthcare Services & Equipment
    IndustryAdvanced Medical Equipment & Technology
    AI synthesis
    GENERATED

    The company's capital structure is highly leveraged, with a debt-to-equity ratio of -1.36, indicating that liabilities significantly exceed equity. Liquidity is constrained, as evidenced by a current ratio of 0.87, and the firm holds only 797,460 EUR in cash and equivalents, which is insufficient to cover its long-term debt of 9,304,120 EUR. This suggests a high dependency on external financing to meet obligations.

    Profitability is severely challenged, with a net loss of 10,809,110 EUR and an operating loss of 10,679,690 EUR, resulting in a negative return on assets of -1.35%. The return on equity is also negative at 1.58%, which is far below the typical performance metrics for the industry. These figures indicate that the company is not generating sufficient returns to justify its capital structure.

    The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no significant geographic diversification reported. This lack of diversification increases the company's exposure to market-specific risks and could limit its ability to grow through new markets or product lines.

    The company's growth trajectory is negative, with a reported revenue of 2,963,330 EUR and a net loss of 10,809,110 EUR. Analysts have noted a last actual EPS of -0.07 EUR and a revenue of 3,305,000,000 EUR, which suggests a challenging outlook for the company's earnings and revenue growth. The company's financial performance indicates a need for strategic adjustments to improve profitability and reduce losses.

    The company faces significant financial risks, including a high liquidity risk due to its negative net cash position and a medium risk of dilution, although the probability is currently low. The company's financial snapshot indicates that it may need to issue additional shares or take on more debt to fund operations, which could dilute existing shareholders' equity. The risk assessment highlights the need for the company to address its liquidity and capital structure issues to avoid further financial distress.

    Recent events, as reflected in the company's financial filings, show a continued decline in profitability and an increase in debt levels. The company's management has not disclosed any significant strategic initiatives or cost-cutting measures that could reverse the current financial trajectory. The lack of positive developments in the company's financial performance raises concerns about its long-term viability and the potential for further losses.

    Key takeaways
    • The company is experiencing significant financial distress, with a net loss and a negative return on assets.
    • Liquidity is constrained, with a current ratio below 1 and insufficient cash to cover long-term debt.
    • The company's profitability is severely challenged, with a negative return on equity and operating losses.
    • There is a lack of geographic and segment diversification, increasing exposure to market-specific risks.
    • The company's growth trajectory is negative, with a need for strategic adjustments to improve financial performance.
    • **margin_outlook_rationale**: The company's operating margin is expected to remain negative due to ongoing losses and high debt servicing costs.
    • **rd_outlook_rationale**: There is no specific information provided on R&D spending or future product development plans.

    Bull / Bear case

    analysis pipeline
    — missing data

    In focus — financials by report

    Valuation

    Market price
    €0,21
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    -€6.8M
    Net cash
    -€8.5M
    Current ratio
    0.9
    Debt / equity
    -1.4
    ROA
    -1.4%
    ROE
    1.6%
    Cash conversion
    CapEx / revenue
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin-360,4 %Bottom quartile
    Net Margin-364,8 %Bottom quartile
    ROE158,1 %Best in class
    D/E-1,36Best in class

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Return On Assets
      net_income / total_assets
    Source documents
    • ALINS.PA Market data — financials · 2026-05-27
    • Intrasense SA Market data — analyst estimates · 2026-05-27

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    ALINS.PACanonical
    Euronext Paris · EUR

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    — missing data
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage